Peminib (Pemigatinib) 13.5mg*14 | Ziska Bangladesh Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: Peminib (Pemigatinib) 13.5mg — Bangladesh

Peminib is a Bangladesh-manufactured generic of pemigatinib produced by Ziska Pharmaceuticals Ltd., one of Bangladesh's established pharmaceutical companies. It is supplied at the 13.5 mg strength in 14-tablet packs — matching the originator's standard starting dose for cholangiocarcinoma. Peminib is Ziska's pemigatinib brand for FGFR2-altered bile duct cancer, offering patients in South Asia and beyond an affordable alternative to the high-priced originator.

Bangladesh has a well-developed generic pharmaceutical industry that supplies much of the developing world, and Ziska is a recognised name within it. Because Peminib comes in the 13.5 mg strength, it is used directly at the standard once-daily dose, making it a straightforward substitute for the originator without any dose conversion.

What Is Peminib Used For?

Peminib is prescribed for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma whose tumour carries an FGFR2 fusion or rearrangement. Cholangiocarcinoma is a rare and aggressive cancer of the bile ducts, often diagnosed late with limited options. Pemigatinib was the first targeted therapy approved for the FGFR2-altered subset, and Peminib delivers the same active ingredient at the standard dose.

How Does Peminib Work?

Pemigatinib, the active ingredient in Peminib, is a selective inhibitor of FGFR1, FGFR2 and FGFR3 kinases. When FGFR2 is fused or rearranged, the receptor stays switched on and drives uncontrolled cancer-cell growth. Peminib blocks this overactive pathway, slowing tumour progression through a targeted mechanism that spares many of the toxicities of conventional chemotherapy.

Indications

  • Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement, confirmed by a validated test.
  • Adult patients who have progressed after at least one prior line of systemic therapy.

Dosage and Administration

The recommended dose is 13.5 mg once daily for 14 consecutive days, followed by 7 days off, in repeating 21-day cycles. Tablets are swallowed whole with water, with or without food. Regular monitoring of phosphate, renal function and eye health is advised, with ophthalmologic evaluation for any visual symptoms.

Side Effects

Common adverse reactions include hyperphosphatemia, diarrhoea, stomatitis, dry mouth, fatigue, nausea and alopecia. Serous retinal detachment is a serious risk that requires prompt reporting of visual changes. Dry eye, nail disorders and elevated liver enzymes are also observed, with most adverse events mild to moderate in severity.

Storage

Store Peminib below 25°C in the original package, away from moisture and direct light, out of the reach of children. Use before the printed expiry date.

Why Choose the GLT?

GLT sources Peminib through an audited Bangladesh-based supply chain and documents every batch, which matters for buyers who need a dependable, traceable generic alternative to the high-priced originator. Compared with the US list price of branded pemigatinib, Bangladesh and other regional generics typically cost a small fraction — often several times lower — making long-term FGFR-targeted therapy far more sustainable. We also provide clear purchase documentation and direct contact for ongoing support.

How to Order Peminib from GLT

To order Peminib 13.5 mg (14 tablets), contact GLT on WhatsApp at +86 15234153837 or email [email protected]. Tell us your quantity, shipping destination and whether you require a prescription or purchase order. We confirm batch details and lead time before dispatch.

FAQ

Is Peminib the same as Pemazyre? Peminib contains the same active ingredient (pemigatinib) at the standard 13.5 mg dose as Pemazyre; it is a generic manufactured in Bangladesh by Ziska Pharmaceuticals.

What strength is Peminib? Peminib is supplied at 13.5 mg, the standard once-daily pemigatinib dose.

Where can I order Peminib? GLT can supply Peminib to international buyers; reach us on WhatsApp or email for availability.

Related Oncology Products

欣可平 XinKePing(阿伐曲泊帕)20mg*10片 | 南京恒生制药 | GLT

欣可平——南京恒生制药(济民可信集团)马来酸阿伐曲泊帕片,原料药与制剂一体化生产,中国大陆

SPINRAZA(诺西那生钠)12mg/5mL | 中国购买 | SMA 疗法 | GLT

渤健首创的反义寡核苷酸 SMA 疗法,已获 NMPA 批准并纳入中国国家医保——从 GLT 购买,价格仅为欧美的一小部分。

康曲欣 KangQuXin(阿伐曲泊帕)20mg×10片 | 北京康蒂尼(Gyre)| GLT

康曲欣 KangQuXin — 阿伐曲泊帕,北京康蒂尼药业(Gyre Therapeutics,纳斯达克:GYRE)出品,中国大陆

Tirzema(替尔泊肽)2.5/5/7.5mg/0.5mL 单剂量注射笔 | Incepta(孟加拉国)| GLT

Tirzema——Incepta Pharmaceuticals 替尔泊肽单剂量注射笔,三种官方规格(2.5/5/7.5mg/0.5mL),用于 2 型糖尿病和体重管理。

Barinib(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Drug International Limited | GLT

由 Drug International Limited(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

奥氟格列隆/奥格列龙(LuciOrfor)0.8–17.2mg 片剂 | 老挝仿制药 口服 GLP-1 | GLT

卢修斯制药(老挝)有限公司出品奥氟格列隆(奥格列龙)仿制药,6 档剂量递增方案,用于体重管理

Baricent(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Incepta Pharmaceuticals Ltd. | GLT

由 Incepta Pharmaceuticals Ltd.(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Olumiant(巴瑞替尼)2mg/4mg 片 | JAK1/JAK2 抑制剂 | 礼来(美国)| GLT

礼来公司的选择性 JAK1/JAK2 抑制剂,用于类风湿关节炎、特应性皮炎和重度斑秃。